Samsung Biologics
27F, 1320-10, Seocho 2-dong, Seocho-gu
Seoul
137-965
Tel: 82-2-2255-8500
Fax: 82-2-2255-8577
Website: http://www.samsungbiologics.com/
60 articles with Samsung Biologics
-
Samsung Biologics breaks ground on Super Plant, the world's largest and most innovative bio-manufacturing facility
11/18/2020
Samsung Biologics officially began construction of its Plant 4 in Incheon, South Korea.
-
Samsung Biologics announces strategic manufacturing partnership with Lilly to accelerate delivery of COVID-19 antibody treatments
11/17/2020
Samsung Biologics' partnership with Eli Lilly and Company is expected to greatly accelerate the global supply for Lilly's COVID-19 antibody therapies through a long-term manufacturing agreement, with the ultimate goal of making antibody treatments more globally accessible for patients.
-
Samsung Biologics' Virtual Exhibition Hall earns top industry award for digital creativity and innovation
11/4/2020
Samsung Biologics' Virtual Exhibition Hall was recently recognized for its highly interactive digital capabilities and virtual reality technology to connect with clients around the world.
-
The life sciences industry is one of the fastest growing in the world. BioSpace provides a rundown of companies announcing facility and job expansions across the U.S. and beyond.
-
Samsung Biologics Establishes Partnership with China Biotech GeneQuantum Healthcare to Collaborate on ADC Development
11/2/2020
Samsung Biologics has entered into a strategic partnership with GeneQuantum Healthcare, a China biotech company, to jointly develop an antibody drug conjugate for the treatment of non-small-cell lung carcinoma, triple-negative breast cancer, and other solid tumors.
-
Samsung Biologics and Checkpoint Therapeutics Expand Manufacturing Partnership for Cosibelimab
11/2/2020
Samsung Biologics Co., Ltd. and Checkpoint Therapeutics, Inc., announced the expansion of a long-term manufacturing partnership for Checkpoint's anti-PD-L1 antibody, cosibelimab.
-
Samsung Biologics' strategic business operations continue to support strong third quarter earnings
10/21/2020
Samsung Biologics maintained steady financial results for its fiscal 2020 third quarter ending September 30, demonstrating confident execution of its ongoing business operations.
-
Samsung Biologics inks development partnership with Dinona for potential COVID-19 treatment
10/20/2020
Samsung Biologics has entered into a partnership agreement with biotech Dinona, further expanding its CDO capabilities to provide a full scope of its development services from cell line development, process development, to non-clinical and clinical material manufacturing.
-
Samsung Biologics partners with BioEleven for cancer immunotherapy development and manufacturing
10/19/2020
Samsung Biologics has entered into a partnership agreement with BioEleven to develop and manufacture BN-101A, a third-generation immunotherapy to treat cancer.
-
Samsung Biologics and AstraZeneca announced on Monday that they have entered a long-term supply agreement, expected to be valued at approximately $330 million.
-
Samsung Biologics signs strategic partnership with Kanaph Therapeutics to develop treatment for retinal diseases
9/23/2020
Samsung Biologics (207940.KS) and Kanaph Therapeutics have entered into a strategic partnership to develop KNP-301, a bi-specific Fc fusion protein intended to treat retinal diseases.
-
Samsung Biologics and AstraZeneca forge strategic manufacturing partnership for global supply
9/22/2020
Samsung Biologics (207940.KS) and AstraZeneca announced a long-term supply agreement, valued at approximately $330.8 million . Under this agreement, Samsung Biologics will provide large-scale commercial manufacturing for drug substance in its Plant 3 as well as drug product to support AstraZeneca's biologics therapeutic
-
A London AI Hub, a Facility Bigger than the Louvre, Are Among the Newest Footprint Expansions in ...
9/3/2020
GlaxoSmithKline has opened a new $13 million research hub in London focused on artificial intelligence. -
Samsung Biologics Posts Strong Second Quarter Earnings With 48.5% Increase In Sales
7/21/2020
Samsung Biologics (KRX: 207940.KS) announced today strong financial results for its fiscal 2020 second quarter ending June 30, 2020 , maintaining steady business performance with a high operating margin at 26.4%. The Company recorded a revenue of KRW 307.7 billion , an increase of 48.5% quarter-on-quarter, and an
-
Samsung Biologics Expands Drug Product Manufacturing Facility in Incheon
7/20/2020
Samsung Biologics (207940.KS) announced a plan to expand its Drug Product (DP) capability in line with increasing market demand and to ensure flexible production capabilities for new and existing clients.
-
Samsung Biologics and ImmuneOncia sign multi-product development and manufacturing agreement
7/15/2020
Samsung Biologics and ImmuneOncia Therapeutics held a signing ceremony for a contract to develop and manufacture five candidate molecules, expanding upon the two companies' existing CDO partnership first established in 2018.
-
Samsung Biologics signs additional development and manufacturing agreement with STCube
7/12/2020
Samsung Biologics has further expanded its partnership with STCube through an additional development and manufacturing service agreement of STM418, an anti-PD1 immuno-oncology candidate.
-
Samsung Biologics Unveils Virtual Exhibition Hall to Digitally Connect with Clients at BIO 2020
6/8/2020
Samsung Biologics announced the launch of a Virtual Exhibition Hall, coinciding with the opening of BIO Digital 2020 week.
-
Samsung Biologics Expands Business Continuity Excellence with Additional ISO 22301 Certification
5/19/2020
Samsung Biologics announced it has attained ISO22301 certification for additional business operations, demonstrating its unsurpassed commitment to ensuring client satisfaction and operational excellence through its world-class business continuity management system.
-
Samsung Biologics and ImmuneOncia Therapeutics Inc. Development and Manufacturing Agreement Accomplishes IND Clearance of IMC-002 (anti-CD47 antibody)
4/23/2020
Samsung Biologics and ImmuneOncia Therapeutics Inc. announced the successful FDA IND approval of IMC-002 under a development and manufacturing agreement with Samsung Biologics since 2018.